Role of Immune Responses After Acute Myocardial Infarction (BATTLE-AMI)
Myocardial Fibrosis
About this trial
This is an interventional treatment trial for Myocardial Fibrosis focused on measuring MRI, Ventricular function, left
Eligibility Criteria
Inclusion Criteria:
1. Stable patients with ST elevation myocardial infarction (STEMI) treated with thrombolytics in the first 6h or the initial of symptoms of MI.
Exclusion Criteria:
- Contraindication or known intolerance to the study drug protocol
- Those with comorbidities such as neoplasm, renal insufficiency (stage 4 or higher)
Patients should be randomized in the first 24 hours of AMI and treated by one of the four combined therapies at least 2h prior to coronary angiogram followed by percutaneous intervention when necessary.
Sites / Locations
- Hospital Sao Paulo - UNIFESPRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Active Comparator
Active Comparator
Active Comparator
rosuvastatin plus clopidogrel
Rosuvastatin plus ticagrelor
simvastatin plus clopidogrel
Simvastatin plus ticagrelor
rosuvastatin 40 mg and clopidogrel 75 mg
Rosuvastatin 40 mg plus ticagrelor 90 mg bid
Simvastatin 40 mg plus clopidogrel 75 mg
Simvastatin 40 mg plus ticagrelor 90 mg bid